Krd-LSR Capsule is a combination pharmaceutical formulation containing Levosulpiride 75 mg and Rabeprazole 20 mg, indicated for the management of gastroesophageal reflux disease (GERD), dyspepsia, and related upper gastrointestinal motility disorders. Levosulpiride, a selective dopamine D2 receptor antagonist, exerts prokinetic and antiemetic effects by enhancing gastrointestinal motility and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and abdominal discomfort. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, promoting mucosal healing and reducing acid-related irritation. The synergistic action of these agents addresses both the motility dysfunction and acid hypersecretion components of gastrointestinal disorders, providing comprehensive symptom relief. Krd-LSR Capsule is generally well-tolerated; however, it should be used with caution in patients with hypersensitivity to either component, and monitoring is advised in those with hepatic or renal impairment. Common adverse effects may include headache, dizziness, dry mouth, and mild gastrointestinal disturbances. This combination therapy is prescribed under medical supervision to optimize therapeutic outcomes and improve patient quality of life in acid-peptic and motility-related gastrointestinal conditions.